The company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer's disease. Following strong phase II results, the company is prioritizing zervimesine for DLB psychosis with registrational trial planning underway, and its cash runway extends through Q2 2027, with START trial results expected in 2027.
Cyborg Score Rationale
Cognition Therapeutics exhibits strong financial strength with a high current ratio despite a low Piotroski F-Score. The company has differentiated its pipeline by refocusing on DLB psychosis after positive Phase 2 results. However, as a clinical-stage asset with modest market capitalization and limited cash runway, execution risk remains significant.
Top Insights
Zervimesine is aimed at addressing psychosis in patients suffering from dementia with Lewy bodies, a condition affecting up to 75% of those diagnosed with the disease.
The company conducted a planned FDA meeting on May 20, 2026, to review Phase 2 results, with a fully funded $80 million Phase 2 START trial readout expected in the second half of 2027.
According to 4 analysts, the average rating for CGTX stock is "Strong Buy," with a 12-month price target of $3.5, representing a potential 186.89% upside from recent trading levels.
Flagship product candidate CT1812 is a first-in-class oral small molecule designed to treat Alzheimer's disease by displacing toxic oligomers of beta-amyloid from synaptic receptors, thereby restoring synaptic function.
Named Competitors
Lecanemab — Anti-amyloid monoclonal antibody for Alzheimer's disease
Donanemab — Anti-tau monoclonal antibody for Alzheimer's disease
Aducanumab — Anti-amyloid monoclonal antibody program
Recent Developments
(March 2026) Received final minutes from FDA meeting on zervimesine for dementia with Lewy bodies psychosis
(April 2026) Announced decision to prioritize zervimesine (CT1812) development for DLB psychosis
(May 2026) Conducted planned FDA meeting to review Phase 2 study results of zervimesine
Open the full interactive Cognition Therapeutics Inc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.